What is the recommended treatment for hepatic steatosis (non‑alcoholic fatty liver disease)?

Treatment of Hepatic Steatosis (Non-Alcoholic Fatty Liver Disease)

All patients with hepatic steatosis require lifestyle modification targeting 7–10% total body weight loss through a Mediterranean diet and vigorous-intensity exercise as first-line therapy; pharmacologic treatment is reserved exclusively for biopsy-proven NASH with significant fibrosis (≥F2). 1

Risk Stratification Determines Treatment Pathway

• Calculate the FIB-4 score using age, AST, ALT, and platelet count as the initial risk assessment tool in every adult with suspected hepatic steatosis. 1
• Low-risk patients (FIB-4 <1.3, liver stiffness <8.0 kPa, or F0-F1 fibrosis on biopsy) should focus exclusively on lifestyle interventions without any pharmacotherapy. 1
• High-risk patients (FIB-4 >2.67, liver stiffness ≥12 kPa, or ≥F2 fibrosis) require immediate referral to hepatology for multidisciplinary care and evaluation of pharmacologic therapy. 1
• Patients over 65 years require a modified FIB-4 threshold of 2.0 (rather than 1.3) to improve specificity and avoid unnecessary referrals. 1

Lifestyle Modification: The Cornerstone of All Treatment

Weight Loss Targets and Expected Outcomes

• 3–5% weight loss improves hepatic steatosis in all patients, including lean individuals. 1
• 5–7% weight loss reduces intrahepatic fat and inflammation. 1
• 7–10% weight loss improves steatohepatitis and potentially reverses fibrosis; this is the primary therapeutic goal for all patients. 1, 2
• Weight reduction must be gradual at <1 kg per week; rapid weight loss can worsen portal inflammation, exacerbate fibrosis, or precipitate acute hepatic failure. 1, 2

Dietary Prescription

• Adopt a Mediterranean dietary pattern as the most evidence-based approach: daily consumption of vegetables, fruits, fiber-rich cereals, nuts, fish or white meat, and olive oil as the primary fat source. 1, 2
• This dietary pattern reduces hepatic fat even without accompanying weight loss. 2
• Create a daily caloric deficit of 500–1000 kcal (approximately 1200–1500 kcal/day for women; 1500–1800 kcal/day for men). 3, 2
• Completely eliminate fructose-containing beverages and sugar-sweetened drinks, as these directly worsen hepatic steatosis. 3, 2
• Replace saturated fats with polyunsaturated (especially omega-3) and monounsaturated fats. 2

Exercise Prescription

• Prescribe 150–300 minutes per week of moderate-intensity aerobic exercise (3–6 METs) or 75–150 minutes per week of vigorous-intensity exercise (≥6 METs). 1, 2
• Vigorous-intensity exercise is specifically required to improve NASH severity and fibrosis; moderate-intensity activity alone reduces steatosis and liver enzymes but does not alter fibrosis. 1, 2
• Add resistance training at least 2 days per week to preserve lean muscle mass and augment metabolic benefits. 1
• Physical activity reduces hepatic steatosis even when weight loss is modest or absent. 2

Management of Metabolic Comorbidities

Diabetes Management

• GLP-1 receptor agonists (semaglutide, liraglutide) are the preferred first-line agents for patients with type 2 diabetes and hepatic steatosis, as they improve both glycemic control and liver histology. 1, 2
• Avoid sulfonylureas and insulin when possible, as they are associated with 1.6-fold and 2.6-fold increased hepatocellular carcinoma risk, respectively. 3, 2
• Metformin may be continued for diabetes management but should not be used as a specific NAFLD treatment, as it has minimal impact on liver histology. 3, 2

Dyslipidemia Management

• Statins are safe, effective, and strongly recommended for all patients with hepatic steatosis and dyslipidemia. 1, 2
• Statins reduce hepatocellular carcinoma risk by approximately 37% and hepatic decompensation risk by 46%. 1, 2
• Do not withhold statins due to unfounded hepatotoxicity concerns; they are both safe and hepatoprotective in NAFLD. 2

Alcohol Guidance

• Limit alcohol intake to ≤30 g/day for men and ≤20 g/day for women in pre-cirrhotic disease. 3, 2
• Complete abstinence from alcohol is mandatory in NASH-related cirrhosis to reduce hepatocellular carcinoma risk. 1, 2
• Even modest daily alcohol intake roughly doubles the risk of adverse hepatic events. 1

Pharmacologic Treatment for Advanced Disease (≥F2 Fibrosis)

Pharmacologic therapy should be initiated only in patients with biopsy-proven NASH and significant fibrosis (≥F2); simple steatosis does not warrant drug treatment. 1, 2

First-Line Pharmacologic Agents

• Resmetirom is the preferred agent where approved for non-cirrhotic NASH with ≥F2 fibrosis, showing histologic improvement in steatohepatitis and fibrosis with an acceptable safety profile. 1
• Semaglutide 0.4 mg daily achieved NASH resolution without worsening fibrosis in 59% of treated patients versus 17% with placebo in randomized trials. 1, 2
• Pioglitazone increases odds of NASH resolution (OR ≈3.2) and advanced fibrosis reversal (OR ≈3.1); modest weight gain (~2.7%) can be mitigated with nutritional counseling or combination therapy with SGLT2 inhibitors or GLP-1 agonists. 1, 2
• Vitamin E 800 IU daily improves steatohepatitis in non-diabetic, non-cirrhotic patients with biopsy-proven NASH, though long-term safety concerns limit routine use. 1, 2

Agents NOT Recommended

• Metformin does not produce clinically meaningful improvement in steatohepatitis histology and should not be prescribed as NAFLD-specific therapy. 3, 2
• Dipeptidyl-peptidase-4 inhibitors showed no benefit in randomized controlled trials. 1

Bariatric Surgery for Eligible Patients

• Consider bariatric surgery for individuals with BMI ≥40 kg/m² (or BMI ≥35 kg/m² with comorbidities) and clinically significant fibrosis when lifestyle measures have failed. 1, 2
• Approximately 85% of patients achieve histologic NASH resolution at one year post-procedure. 2
• Bariatric surgery is contraindicated or lacks established safety in patients with cirrhosis or very high BMI with advanced fibrosis. 2

Surveillance and Monitoring Strategy

Low-Risk Patients (F0-F1)

• Conduct annual follow-up with repeated non-invasive fibrosis tests (FIB-4, liver stiffness measurement). 1
• Monitor serum transaminases (ALT, AST) every 6–12 months. 2

High-Risk Patients (≥F2 Fibrosis)

• Refer to hepatology for multidisciplinary care and close monitoring for cirrhosis, hepatocellular carcinoma, and related complications. 1
• Use transient elastography with controlled attenuation parameter (CAP) and liver stiffness measurements to gauge therapeutic response. 1

Cirrhotic Patients (F4)

• Perform abdominal ultrasound every 6 months for hepatocellular carcinoma surveillance; the annual HCC incidence in NASH cirrhosis is 2–3%. 1, 2
• Conduct screening endoscopy for esophageal varices at the time of cirrhosis diagnosis; repeat if liver stiffness ≥20 kPa or thrombocytopenia is present. 1
• Refer to a liver transplant center when decompensated cirrhosis occurs or standard transplant criteria are met. 1
• No disease-specific pharmacotherapy for NASH is recommended in the cirrhotic stage; management focuses on metabolic drug adaptation, nutritional counseling, and surveillance. 1

Critical Pitfalls to Avoid

• Do not assume normal ALT excludes advanced fibrosis; approximately one-quarter of patients with advanced fibrosis have persistently normal aminotransferases. 1
• Do not initiate pharmacologic therapy without biopsy confirmation of NASH; simple steatosis carries an excellent prognosis and does not warrant drug treatment. 1, 2
• Do not pursue rapid weight loss exceeding 1 kg per week, as this can precipitate hepatic decompensation. 1, 2
• Do not discontinue statins in patients with dyslipidemia due to unfounded hepatotoxicity concerns. 2
• Avoid chronic use of medications that worsen hepatic steatosis: corticosteroids, amiodarone, methotrexate, tamoxifen, estrogen therapy, tetracyclines, and valproic acid. 1, 2